MicroRNA 660 (miR-660)

MicroRNA 660 (miR-660) is a short, non-coding RNA molecule that regulates gene expression post-transcriptionally in human cells[1][7]. It acts primarily by base-pairing with target mRNAs to repress their translation or drive mRNA degradation. In cancers such as lung and breast cancer, miR-660 exhibits context-dependent roles: it can act as a tumor suppressor, for example by downregulating MDM2 (thus activating p53-dependent anti-tumor responses in lung cancer)[3], or as an oncogene, for instance by promoting proliferation and metastasis in breast cancer through targeting genes like TET2 and TFCP2 and modulating signaling pathways such as PI3K/AKT/mTOR[4][6]. miR-660 is being investigated as both a therapeutic target and a biomarker for prognosis and patient stratification in oncology[3][4][5][6]. Current investigations into drugs like regorafenib and diindolylmethane suggest potential for miR-660 modulation in cancer treatment, although delivery and specificity remain major challenges for therapeutic development[5].

Other names

MIR660hsa-mir-660MIRN660mir-660microRNA 660miR-660-5p

For drugs: Targeting miR-660, potentially reducing its oncogenic effects or restoring tumor suppressor functions by altering its interaction with mRNA partners. Post-transcriptional repression of specific target genes—direct repression of MDM2 in lung cancer, TET2 and TFCP2 in breast cancer.